CSL is leveraging its integrated global portfolio to bring urgently needed therapeutic COVID-19 treatments to patients around the world, two R&D leaders recently told BioSpace, a life science industry news and careers site.
Given the company’s expertise in vaccines, monoclonal antibodies and recombinant technology, we are well-positioned to focus not only on preventing the disease but also on treating the damage it inflicts on patients who contract it, said Deirdre BeVard, Senior Vice President for Research and Development Strategic Operations, and Vicky Pirzas, Vice President of Recombinant Product Development.
Read the article here: Driven by Our Promise to Deliver for COVID-19 Patients
